SOURCE: Medivation

Medivation

February 10, 2012 16:30 ET

Medivation Announces Participation at Upcoming Investor Conferences

SAN FRANCISCO, CA--(Marketwire - Feb 10, 2012) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following investor conferences in February:

  • Patrick Machado, chief business and financial officer, will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16 at 8:00am Eastern Time at the Waldorf-Astoria Hotel in New York City.

  • David Hung, M.D., president and chief executive officer, will present at the Citi 2012 Global Healthcare Conference on Tuesday, February 28 at 9:30am Eastern Time at the Waldorf-Astoria Hotel, in New York City.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug MDV3100 in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at www.medivation.com.

Contact Information

  • Contacts:
    Patrick Machado
    Chief Business & Financial Officer
    (415) 829-4101

    Anne Bowdidge
    Sr. Director, Investor Relations
    (650) 218-6900